Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68,657 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors.
Mundra V, Yang Y, von Itzstein MS, Fattah F, Gonugunta AS, Hannan R, Pop LM, Zhang Y, Wang Y, Sheffield T, Xie Y, Dowell JE, Homsi J, Rashdan S, Park J, Li QZ, Wakeland EK, Gerber DE. Mundra V, et al. Among authors: park j. Transl Oncol. 2023 Aug;34:101689. doi: 10.1016/j.tranon.2023.101689. Epub 2023 Jun 6. Transl Oncol. 2023. PMID: 37285748 Free PMC article.
Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud's-Like Phenomenon.
Khan S, von Itzstein MS, Lu R, Bermas BL, Karp DR, Khan SA, Fattah FJ, Park JY, Saltarski JM, Gloria-McCutchen Y, Xie Y, Li QZ, Wakeland EK, Gerber DE. Khan S, et al. Among authors: park jy. Oncologist. 2020 May;25(5):e753-e757. doi: 10.1634/theoncologist.2019-0666. Epub 2020 Mar 13. Oncologist. 2020. PMID: 32167195 Free PMC article.
Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?
von Itzstein MS, Khan S, Popat V, Lu R, Khan SA, Fattah FJ, Park JY, Bermas BL, Karp DR, Ahmed M, Saltarski JM, Gloria-McCutchen Y, Xie Y, Li QZ, Wakeland EK, Gerber DE. von Itzstein MS, et al. Among authors: park jy. Oncologist. 2020 Aug;25(8):e1242-e1245. doi: 10.1634/theoncologist.2019-0911. Epub 2020 Jun 3. Oncologist. 2020. PMID: 32400023 Free PMC article.
Accessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology?
von Itzstein MS, Smith ML, Railey E, White CB, Dieterich JS, Garrett-Mayer L, Bruinooge SS, Freedman AN, De Moor J, Gray SW, Park JY, Yan J, Hoang AQ, Zhu H, Gerber DE. von Itzstein MS, et al. Among authors: park jy. JCO Oncol Pract. 2021 Jul;17(7):e999-e1011. doi: 10.1200/OP.20.00927. Epub 2021 May 10. JCO Oncol Pract. 2021. PMID: 33970688 Free PMC article.
Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors.
Ahmed M, von Itzstein MS, Sheffield T, Khan S, Fattah F, Park JY, Popat V, Saltarski JM, Gloria-McCutchen Y, Hsiehchen D, Ostmeyer J, Khan SA, Sultana N, Xie Y, Li QZ, Wakeland EK, Gerber DE. Ahmed M, et al. Among authors: park jy. J Immunother Cancer. 2021 Jun;9(6):e002349. doi: 10.1136/jitc-2021-002349. J Immunother Cancer. 2021. PMID: 34127546 Free PMC article.
Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy.
von Itzstein MS, Gonugunta AS, Sheffield T, Homsi J, Dowell JE, Koh AY, Raj P, Fattah F, Wang Y, Basava VS, Khan S, Park JY, Popat V, Saltarski JM, Gloria-McCutchen Y, Hsiehchen D, Ostmeyer J, Xie Y, Li QZ, Wakeland EK, Gerber DE. von Itzstein MS, et al. Among authors: park jy. Cancers (Basel). 2022 Mar 4;14(5):1327. doi: 10.3390/cancers14051327. Cancers (Basel). 2022. PMID: 35267634 Free PMC article.
T-cell tolerant fraction as a predictor of immune-related adverse events.
Ostmeyer J, Park JY, von Itzstein MS, Hsiehchen D, Fattah F, Gwin M, Catalan R, Khan S, Raj P, Wakeland EK, Xie Y, Gerber DE. Ostmeyer J, et al. Among authors: park jy. J Immunother Cancer. 2023 Aug;11(8):e006437. doi: 10.1136/jitc-2022-006437. J Immunother Cancer. 2023. PMID: 37580069 Free PMC article.
Distinct autoantibody profiles across checkpoint inhibitor types and toxicities.
Mu-Mosley H, von Itzstein MS, Fattah F, Liu J, Zhu C, Xie Y, Wakeland EK, Park JY, Kahl BS, Diefenbach CS, Gerber DE. Mu-Mosley H, et al. Among authors: park jy. Oncoimmunology. 2024 May 9;13(1):2351255. doi: 10.1080/2162402X.2024.2351255. eCollection 2024. Oncoimmunology. 2024. PMID: 38737792 Free PMC article. Clinical Trial.
Trends in physician Medicare payments by gender and specialty.
He L, Arvisais-Anhalt S, Araj E, Yin H, Reimold SC, Sanghavi R, Park JY. He L, et al. Am J Med Sci. 2023 Jul;366(1):79-81. doi: 10.1016/j.amjms.2023.04.017. Epub 2023 Apr 22. Am J Med Sci. 2023. PMID: 37094631 No abstract available.
68,657 results
You have reached the last available page of results. Please see the User Guide for more information.